AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI (durvalumab) has been accepted and granted Priority Review in the U.S. for the treatment of patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers. The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if approved, would offer significant improvements over available options by demonstrating safety ...